Did you mean amitifadine of en 100 of dov 21,947 of アミティファジン?
Displaying drugs 101 - 125 of 234 in total
NT-219
Investigational
AD-214
Investigational
QS-21
QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment. It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being...
Investigational
Matched Name: … QS-21 …
Matched Description: … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies …
Matched Description: … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies …
MDX-210
Investigational
Bicifadine
Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.
Investigational
Matched Description: … Bicifadine (DOV-220075) is a nonopioid analgesic. …
NEO-212
Investigational
BNC-210
BNC-210 is under investigation in clinical trial NCT04951076 (A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-traumatic Stress Disorder (PTSD)).
Investigational
GTS-21
GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition...
Investigational
Matched Name: … GTS-21 …
Matched Description: … GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic ... GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in ... In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated …
Matched Description: … GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic ... GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in ... In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated …
EGS21
EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate drug in...
Investigational
Matched Description: … immune mediated diseases, such as Crohn's disease, hepatitis, non-alcoholic steatohepatitis (NASH) or …
SLx-2101
SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.
Investigational
NPS-2143
Investigational
OSE-2101
Investigational
BB 21217
BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as idecabtagene vicleucel (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for memory-like T cells.
Investigational
MBX-2109
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
AGA2115
AGA2115 is a humanized bispecific antibody neutralizing both sclerostin and Dickkopf-1. Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.
Investigational
XEN-2174
XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET). NET is the primary mechanism regulating the biological effects of...
Investigational
KOS-2187
KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).
Investigational
Matched Description: … KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment …
SRT-2104
SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular, and Diabetes Mellitus, Type 2.
Investigational
PZM21
PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine.
Experimental
NX-210c
Investigational
JE-2147
Experimental
MDX-214
MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector cells. It is developed for the treatment of EGF-R overexpressing cancers.
Investigational
ITI-214
ITI-214 is under investigation in clinical trial NCT03489772 (Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement).
Investigational
Displaying drugs 101 - 125 of 234 in total